Dr. Reddy’s to Acquire Janssen’s Stugeron Brand for $50.5 Million

Dr. Reddy’s Laboratories Ltd. said late Wednesday it has signed a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the Stugeron brand portfolio for $50.5 million.

The deal covers Stugeron Forte, Stugeron Plus and related assets across 18 markets in Asia-Pacific, Europe, Middle East, and Africa, with India and Vietnam as key markets, the company said in an exchange filing.

The Stugeron brand, which contains Cinnarizine, is indicated for treating vestibular disturbances and vertigo.